Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,751 total articles
Vince (VNCE) just cleared a high hurdle: a Q2 beat and better DTC traction. The OVO acquisition is less an incremental bolt-on than a stress test of a new operating model. If Vince can convert sales mix and protect margins, valuation looks inexpensive relative to its FCF and EV/EBITDA. This is a mid-term swing trade: buy on weakness, size for a 45-…
Pagaya (PGY) is a buy at $20.80. The company pairs strong recent revenue and free-cash-flow generation with below-peer valuation multiples and a shift toward fee-based, asset-light products that reduce interest-rate sensitivity. Entry $20.80, stop $17.00, target $30.00 over a 180-trading-day horizon.
Faeth Therapeutics (FTH) is a clinical-stage immunotherapy company trading at a market cap near $900M. We prefer FTH ahead of a year-end 2026 PIKTOR endometrial cancer (EC) data readout and the program's planned expansion into HR+/HER2- breast cancer. The combination of Fast Track designation, a compact float, and modest short interest creates an a…
Brookfield Asset Management (BAM) offers a 4.3% yield, strong free cash flow ($2.31B) and multiple growth levers including a recent $2.8B acquisition. Near-term technicals are oversold and valuation can re-rate if asset monetization and fee growth accelerate.
Vor Biopharma looks like a funded replication bet: telitacicept delivered a meaningful clinical signal in China and the company has since raised capital to advance global development. At a market cap of about $1.29B and with active short interest, the stock offers a high-risk, high-reward trade if upcoming clinical and execution milestones confirm …
LB Pharmaceuticals (LBRX) is a small-cap biotech advancing LB-102, a Phase 3-ready oral antipsychotic for acute schizophrenia. With topline NOVA-2 results moved into H1 2027 and a balance sheet that management says funds operations through Q2 2029, the stock looks like a buyable pullback around $42. This long trade targets $60 over a 180 trading da…
We upgrade TransMedics (TMDX) to a tactical long ahead of multiple 2027 clinical and commercial catalysts. The company is growing revenue (Q2 revenue $189.9M, +20.7% YoY) while reinvesting heavily in kidney OCS expansion and manufacturing, compressing near-term margins. At a $3.0B market cap and P/E around 19.8, the valuation already reflects a mix…
SK hynix sits at the intersection of memory, custom packaging and system-level AI acceleration. This trade idea argues for a defined long with a mid-to-long-term horizon, capitalizing on continued AI server deployments and the company’s deep NAND/DRAM integration. Entry, stop and targets are provided with catalysts and balanced risks.
Brookfield trades near its 52-week low while fundraising momentum, an expanding Wealth & Insurance mix, and a likely investor-day update create a clear, actionable swing trade. Technicals show oversold conditions and elevated short activity that can fuel a quick rebound. I recommend a tactical long with defined risk and a mid-term horizon tied to u…
Cboe (CBOE) looks attractive after a summer pullback: $27.8B market cap, 12.9 EPS and ~21x P/E, strong free cash flow of roughly $1.9B, and specific product moves that should boost volumes when volatility spikes. Technicals show the stock is oversold (RSI ~34) and below its short-term moving averages, creating an entry opportunity. Trade plan: ente…
Interparfums just checked two boxes investors care about: governance reinforcement via two experienced luxury executives joining the board and shareholder approval of incentive plan extensions. Backed by strong cash generation, a resilient margin profile, and ongoing brand deals (Coach renewal, Goutal acquisition), the setup supports a swing trade …
MasterBrand (MBC) looks stretched on fundamentals and price action after an expensive acquisition and a string of operational misses. With EV/EBITDA near 25.4, negative EPS, and a broken moving-average structure, we prefer a tactical short from $6.56 with an initial target at $5.00 and a stop at $8.25. This trade is a mid-term tactical idea (45 tra…
AeroVironment (AVAV) is trading like a company that will overpay for M&A and cripple margins. The facts on the ground - low leverage, multi-hundred-million-dollar program wins, improving momentum and a reasonable enterprise value - suggest that fear is overdone. This trade idea lays out a mid-term long with a clear entry, stop and target and the ca…
Alibaba looks positioned to report strong Q2 results driven by continued China commerce recovery and a high-growth cloud business with improving margins. The market has already priced in headline regulatory overhang; a clean print and upward cloud-margin commentary could drive a meaningful re-rating. I'll lay out an actionable long trade with entry…
Vermilion Energy (VET) looks mispriced today relative to a plausible 2028 cash-flow inflection driven by earlier asset rationalization, disciplined capital allocation, and steady dividends. At roughly $12.65 today, the stock implies little upside for improved fundamentals. This trade idea lays out an entry at $12.65, a stop at $10.90 and a target o…
Alliance Resource Partners (ARLP) yields ~9% today and offers an attractive risk/reward for income-focused investors. Free cash flow of $350M, a modest debt-to-equity ratio of 0.33 and a P/E near 12.6 underpin the distribution. I outline an actionable long trade with precise entry, stop and target, a rationale tied to fundamentals and catalysts, an…
VALE S.A. offers a blend of cyclical iron-ore cash flow and growing energy-transition metals exposure (nickel/cobalt) that supports its current valuation. With a market cap near $61.7B, a ~4.9% dividend yield and a manageable technical setup, we target a move back toward the 52-week high. Entry at $14.40, stop at $13.60 and target at $17.94 for lon…
Ternium (TX) looks like a reasonable mid-term long: industrial demand in Mexico is improving, the stock trades at ~0.9x book and a 16x P/E with a 3.9% yield, and price sits near its 52-week high at $58.11. That said, free cash flow dynamics and contingent liabilities warrant a tight stop and a modest position size. This trade plan targets a measure…
Coeur Mining (CDE) looks attractive on a mid-term swing after a Q3 dip. The company generates strong free cash flow (about $1.16B last reported), trades below its 52-week high, and carries minimal net debt. We lay out an actionable entry at $19.50, a stop at $17.00 and a target of $25.00 with a mid-term (45 trading days) horizon.
Western Midstream (WES) combines a top-tier midstream footprint, steady free cash flow generation and an attractive distribution yield (about 7.8%). With FCF of roughly $1.22B, a market cap near $19.5B and EV/EBITDA about 11.5x, WES looks positioned to deliver distribution growth and total return over the next 45 trading days. This trade idea lays …
Oracle is trading well off its 52-week high and pricing in elevated capital spending and execution risk. Still, a 120% cloud infrastructure growth narrative, $664B in remaining performance obligations, and a cheaper entry into the AI infrastructure cycle create an asymmetric trade. This idea lays out a long trade with clear entry, stop and target, …
Palantir is trading like an AI mega-cap but is really an enterprise software platform with robust FCF and government durability. At $176, the name carries sky-high multiples (P/E ~139, EV/sales ~67.7) but also meaningful fundamentals - $3.36B in free cash flow, ROE ~31% and double-digit projected revenue/earnings growth. This trade buys a disciplin…
Nano Labs is a small-cap Chinese fabless chip designer trading at a $51.5m market cap. The company reported sharp H1 2026 losses driven by cryptocurrency fair-value swings, but is pushing into AI hardware (iPollo ClawPC A1 Mini) and exploring North America AI infrastructure with a partner. The stock is cheap on headline metrics, technically set for…
Salesforce pulled back after Dreamforce but fundamentals and capital return programs make the stock attractive. With a market cap near $206B, 2026 earnings power, and a record buyback cadence, this trade targets a rebound to $280 over the next 45 trading days with a defined stop at $232 to limit downside.
SK hynix trades cheaply relative to broader tech while sitting at the intersection of three positive trends: surging AI memory demand, a deepening NVIDIA partnership, and a potential manufacturing tie-up with Intel that would bring memory production to the U.S. Buy SKHY at current levels with a 180-trading-day horizon; manage risk with a clear stop…
